• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Oruka Therapeutics (ORKA) Fully Valued As Psoriasis Pipeline Hopes Face A Pullback?

    Simply Wall St·09/13/2026 20:13:59
    语音播报

    Oruka Therapeutics (ORKA) has quietly moved onto more investor watchlists after a strong year to date. The biotech is now valued at about US$6.1b, with shares last closing at US$92.38.

    Recent trading has cooled, with a 30 day share price return down 16.8% and a flat 7 day move. However, the 90 day share price return of 34.16% and a very large 1 year total shareholder return of about 5x show that momentum in Oruka Therapeutics is still skewed toward earlier buyers reacting to shifting expectations around its psoriasis pipeline and perceived risk profile.

    Scan the psoriasis pipeline moves at Oruka Therapeutics, then size up other high-momentum biotech ideas with strong balance sheets using our curated list of solid balance sheet and fundamentals (23 results).

    After a roughly 5x one year return and a sharp recent pullback, Oruka Therapeutics now sits between euphoria and hesitation. Is the heavier lifting on the share price already done, or does the valuation still leave meaningful upside?

    Price to Book of 5.5x: Is it justified?

    On a simple yardstick, Oruka Therapeutics is priced well above much of the biotech sector. The stock trades at a P/B of 5.5x, compared with 2.3x for the broader US biotechs group. This means investors are currently paying more than twice the industry average for each dollar of net assets at the recent $92.38 share price.

    P/B compares a company’s market value to its accounting equity. For a clinical stage biotech like Oruka Therapeutics, that usually reflects how the market is weighing the value of the drug pipeline, the cash on hand, and the likelihood that today’s research spending eventually turns into commercial products.

    Here, the multiple is doing a lot of heavy lifting. The business has reported no revenue, is currently loss making with a net loss of $109.688m, and analysts do not expect it to generate revenue or reach profitability over the next three years. A 5.5x P/B against that backdrop indicates that investors are comfortable paying a premium for the psoriasis programs and future optionality rather than current financial performance.

    Set against its closest peers, the story looks different. While Oruka Therapeutics trades rich to the wider US biotech industry average, its 5.5x P/B screens as low when lined up against a peer set that sits at 70.2x on the same metric. That contrast underlines how much sentiment can vary between early stage drug developers and points to a wide range of expectations around eventual payoff from R&D pipelines.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 5.5x (OVERVALUED compared to the US Biotechs industry average, LOWER than the peer average).

    Still, the story around Oruka Therapeutics can change quickly if psoriasis trial data disappoints or if funding conditions tighten for loss making biotechs.

    Find out about the key risks to this Oruka Therapeutics narrative.

    Next Steps

    Big moves in Oruka Therapeutics can feel exciting or uncomfortable, depending on where you bought in. Pressure test the story with the detailed risk breakdown and then judge the 4 important warning signs.

    Looking for more Oruka Therapeutics style ideas?

    If Oruka Therapeutics has sharpened your focus on risk, return and balance sheet strength, it makes sense to widen your search before the next wave of opportunities moves.

    Use the Simply Wall St screener to filter for fresh ideas that match your risk tolerance and return goals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.